TY - JOUR
T1 - In vitro activity of tebipenem and comparator agents against bacterial pathogens isolated from patients with cancer
AU - Gerges, Bahgat
AU - Rosenblatt, Joel
AU - Shellburne, Samuel A.
AU - Chaftari, Anne Marie
AU - Hachem, Ray
AU - Raad, Issam
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background: Tebipenem is a broad-spectrum orally administered carbapenem antibiotic that could be an alternative to IV carbapenems. The current study evaluated in vitro activity of tebipenem against bacterial isolates recovered from patients with cancer. Methods: A total of 611 bacterial pathogens recently isolated from patients with cancer were tested for susceptibility to tebipenem and comparators. CLSI-Approved broth microdilution methods were used. MIC50, MIC90, MIC range and percentage susceptibility calculations were made using FDA breakpoints when available. Results: Tebipenem had a low MIC90 for most Gram-positive and Enterobacterales isolates. Tebipenem MIC90 ranged from 0.06 to 0.25 mg/L for all tested Enterobacterales. Conclusions: Oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted.
AB - Background: Tebipenem is a broad-spectrum orally administered carbapenem antibiotic that could be an alternative to IV carbapenems. The current study evaluated in vitro activity of tebipenem against bacterial isolates recovered from patients with cancer. Methods: A total of 611 bacterial pathogens recently isolated from patients with cancer were tested for susceptibility to tebipenem and comparators. CLSI-Approved broth microdilution methods were used. MIC50, MIC90, MIC range and percentage susceptibility calculations were made using FDA breakpoints when available. Results: Tebipenem had a low MIC90 for most Gram-positive and Enterobacterales isolates. Tebipenem MIC90 ranged from 0.06 to 0.25 mg/L for all tested Enterobacterales. Conclusions: Oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85180101685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85180101685&partnerID=8YFLogxK
U2 - 10.1093/jacamr/dlad132
DO - 10.1093/jacamr/dlad132
M3 - Article
C2 - 38089460
AN - SCOPUS:85180101685
SN - 2632-1823
VL - 5
JO - JAC-Antimicrobial Resistance
JF - JAC-Antimicrobial Resistance
IS - 6
M1 - dlad132
ER -